Insurers will not cover obesity drugs that will cost users €2,500-plus a year
As a result, it will be available only on private prescription at a cost of €215 or more a month. That equates to an annual ...
STAT6h
Vertex pain pill dominates earnings call discussion
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
pharmaphorum20h
High-dose semaglutide ramps up weight loss, says Novo
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...